- Trials with a EudraCT protocol (130)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (148)
130 result(s) found for: neuroblastoma.
Displaying page 1 of 7.
EudraCT Number: 2005-005778-63 | Sponsor Protocol Number: NB1-STI571 | Start Date*: 2005-12-20 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma | |||||||||||||
Medical condition: High risk Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003832-96 | Sponsor Protocol Number: ChIm-NB-PL | Start Date*: 2021-10-13 | |||||||||||||||||||||
Sponsor Name:Jagiellonian University Medical College | |||||||||||||||||||||||
Full Title: Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease | |||||||||||||||||||||||
Medical condition: Recurrent or progression of neuroblastoma or neuroblastoma refractory to first-line treatment | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001811-16 | Sponsor Protocol Number: PS21GAP | Start Date*: 2022-12-19 | |||||||||||
Sponsor Name:Princess Maxima Center for pediatric oncology | |||||||||||||
Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003606-33 | Sponsor Protocol Number: PK 2008 03 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Pilot study to investigate the feasibility of 13-cis-Retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma | |||||||||||||
Medical condition: High risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002996-36 | Sponsor Protocol Number: 15TETE04 | Start Date*: 2021-06-23 | ||||||||||||||||
Sponsor Name:INSTITUT CLAUDIUS REGAUD | ||||||||||||||||||
Full Title: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing som... | ||||||||||||||||||
Medical condition: Recurrent or refractory neuroblastoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005398-30 | Sponsor Protocol Number: dopa | Start Date*: 2013-05-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA | |||||||||||||
Full Title: Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in study of neuroblastoma: comparison with 123I-MIBG scintigraphy | |||||||||||||
Medical condition: patients wiht NB onset with high probability to return in stages 3 and 4 of the disease on the basis of the ultrasound images or TC. May also be included with the two-stage amplification of N-MYC | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004864-69 | Sponsor Protocol Number: HSJD-HR-NB-Ch14.18 | Start Date*: 2014-05-21 | |||||||||||
Sponsor Name:Fundació Sant Joan de Deu de Barcelona | |||||||||||||
Full Title: Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma... | |||||||||||||
Medical condition: High-risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004862-15 | Sponsor Protocol Number: MIITOP-0607 | Start Date*: 2007-11-09 | |||||||||||
Sponsor Name:Centre Oscar Lambret | |||||||||||||
Full Title: Etude de Phase II de l'association Méta-lodobenzylguanidine I131 (MIBGI131) et Topotécan dans le traitement des neuroblastomes métastatiques réfractaires ou en rechute. | |||||||||||||
Medical condition: Neuroblastome (métastaique réfractaire) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002221-11 | Sponsor Protocol Number: RHMCHI0811 | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta in children with relapsed/refractory neuroblastoma | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000915-80 | Sponsor Protocol Number: NB 2006 05 | Start Date*: 2005-09-06 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A phase II study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004883-37 | Sponsor Protocol Number: NB2015LR | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR) | |||||||||||||
Medical condition: Neuroblastoma, low or intermediate risk | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004445-36 | Sponsor Protocol Number: LuDO-N | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. | |||||||||||||
Medical condition: Primary refractory or relapsed high-risk neuroblastoma. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003130-27 | Sponsor Protocol Number: 2015/2294 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chem... | |||||||||||||
Medical condition: Very High Risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) AT (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001042-18 | Sponsor Protocol Number: J1O-MC-JZHD | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma | |||||||||||||
Medical condition: Relapsed/Refractory Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001267-63 | Sponsor Protocol Number: SIOPENRNET001 | Start Date*: 2005-07-15 |
Sponsor Name:St. Anna Kinderspital | ||
Full Title: Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma | ||
Medical condition: neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005104-25 | Sponsor Protocol Number: INV500 | Start Date*: 2018-01-02 | |||||||||||||||||||||||||||||||
Sponsor Name:Nova BioPharma Limited | |||||||||||||||||||||||||||||||||
Full Title: Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requi... | |||||||||||||||||||||||||||||||||
Medical condition: Neuroblastoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004481-34 | Sponsor Protocol Number: Uni-Koeln-1694 | Start Date*: 2015-03-12 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL... | |||||||||||||
Medical condition: Recurrent, progressive or newly diagnosed high risk neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001068-31 | Sponsor Protocol Number: 2019/2894 | Start Date*: 2019-09-24 | ||||||||||||||||
Sponsor Name:Gustave Roussy | ||||||||||||||||||
Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p... | ||||||||||||||||||
Medical condition: Very High Risk Neuroblastoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) SI (Ongoing) IT (Ongoing) GR (Ongoing) CZ (Ongoing) NO (Ongoing) BE (Ongoing) SE (Ongoing) SK (Ongoing) ES (Ongoing) DE (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000072-42 | Sponsor Protocol Number: RG_11-087 | Start Date*: 2013-02-06 | |||||||||||
Sponsor Name:The University of Birmingham | |||||||||||||
Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) DK (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) AT (Completed) DE (Prematurely Ended) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003713-33 | Sponsor Protocol Number: 70903 | Start Date*: 2020-03-02 | |||||||||||
Sponsor Name:Princess Máxima Center for pediatric oncology | |||||||||||||
Full Title: Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123]I-mIBG scanning | |||||||||||||
Medical condition: Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.